News
Explore why INmune Bio, Inc. is a speculative Strong Buy for high-risk investors. Click for the upcoming catalysts that make ...
Topline data were announced from two phase 3 trials evaluating MR-107A-02 for the treatment of moderate to severe acute pain.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback